Full Press Release Details
pSivida Out-licenses EMEA Rights for Durasert
Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIEN Improves pSivida s Revenue
WATERTOWN, MA., July 10, 2017 pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release drug
products and technologies, today announced an amendment of its exclusive license and collaboration agreement with Alimera Sciences, Inc. (NASDAQ: ALIM) that grants Alimera rights to pSivida s Durasert three-year treatment for posterior
segment uveitis (Durasert) in Europe, the Middle East and Africa (EMEA). With this license, Alimera plans to pursue a secondary indication for ILUVIEN for posterior segment uveitis in EMEA, which could accelerate the uveitis indication approval as
well as commercialization. pSivida retains commercialization rights for posterior segment uveitis in all other countries, including the United States. The amended agreement also modifies the companies existing global licensing agreement for
ILUVIEN for the treatment of diabetic macular edema (DME).
Key terms of the restructured global licensing agreement for ILUVIEN include:
Benefits of the EMEA out-license and revised ILUVIEN agreement for pSivida include:
Today s announcement fulfills a core
pSivida objective to out-license Durasert EMEA rights as a means to optimize product value, said Nancy Lurker, President and CEO of pSivida. We believe the EMEA
out-license to Alimera, a company that is familiar with the complexity of the EU reimbursement environment and is currently marketing to target specialty physicians, could accelerate commercialization uptake
and revenue realization for pSivida. The EMEA revenue opportunity for Durasert is estimated to be $30 to $50 million, and in the US it is estimated to be $80 to $120 million. We remain on track to file an NDA with the FDA by the end of
this year. In parallel, the restructured global collaboration agreement benefits our shareholders as we immediately begin to recognize royalty income from sales of ILUVIEN as well as increase its long-term revenue opportunity.
Posterior segment uveitis is a chronic, non-infectious inflammatory disease affecting the posterior segment of the
eye, often involving the retina, which is believed to be a leading cause of blindness in the developed and developing countries. It affects people of all ages, producing swelling and destroying eye tissues, which can lead to severe vision loss and
blindness. In the U.S. and EU, posterior uveitis affects approximately 200,000 people, annually. Today, patients with posterior uveitis are typically treated with systemic steroids, but over time frequently develop serious side effects that can
limit effective dosing. Patients then often progress to steroid-sparing therapy with systemic immune suppressants or biologics, which themselves can have severe side effects including an increased risk of cancer.
pSivida Corp. (www.psivida.com),
headquartered in Watertown, MA, is a leader in the development of sustained-release drug products for treating eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments
for back-of-the-eye diseases. The most recent, ILUVIEN , a micro-insert
for diabetic macular edema,
licensed to Alimera Sciences, Inc. is currently sold directly in the U.S. and three EU countries. Retisert , an implant for posterior
uveitis, is licensed to and sold by Bausch & Lomb Inc. pSivida s lead product candidate, Durasert micro-insert for posterior segment uveitis is being independently developed. Two pivotal Phase 3 clinical trials achieved their
primary efficacy endpoint at six months of follow-up with statistical significance. pSivida s pre-clinical development program is focused on using its core platform
technology, Durasert, to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases. To learn more about pSivida please visit www.psivida.com and
connect on Twitter, LinkedIn, Facebook and Google+.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or
developments that we intend, expect or believe may occur in the future are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated
or implied in our forward-looking statements include uncertainties with respect to: our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; further impairment of our intangible assets;
successful commercialization of, and receipt of revenues from, ILUVIEN for diabetic macular edema ( ILUVIEN ), which depends on Alimera s ability to continue as a going concern
and the effect of pricing and reimbursement decisions on sales of ILUVIEN; the number of clinical trials and data required for the Durasert three-year uveitis marketing approval applications in the U.S. and EU; our ability to file and the timing of
filing and acceptance of the Durasert three-year uveitis marketing approval applications in the U.S.; our ability to use data in a U.S. NDA from clinical trials outside the U.S.; ours and Alimera s ability to successfully commercialize Durasert
three-year uveitis, if approved; consequences of fluocinolone acetonide side effects; potential declines in Retisert royalties; efficacy and our future development of an implant to treat
severe osteoarthritis; our ability to successfully develop product candidates, initiate and complete clinical trials and receive regulatory approvals; our ability to market and sell products; the success of current and future license agreements,
including our agreements with Alimera; termination or breach of current license agreements, including our agreements with Alimera; our dependence on contract research organizations, vendors and investigators; effects of competition and other
developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product
liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; effects of the potential U.K. exit from the EU; legislative or regulatory changes; volatility of stock
price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. You should read and interpret any forward-looking statements in light of these risks. Should known or unknown
risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you
consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future
changes makes it clear that any projected results expressed or implied in such statements will not be realized.
Michael Polyviou/Doug Sherk Investors
212.850.6020; 646-445-4800